Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Priadel 400mg modified-release tablets
0402030K0BFAAAF
|
Priadel (Tablet) | Lithium carbonate | Central Nervous System | 81,520 |
|
Priadel 200mg modified-release tablets
0402030K0BFABAI
|
Priadel (Tablet) | Lithium carbonate | Central Nervous System | 67,316 |
|
Lithium carbonate 400mg modified-release tablets
0402030K0AAAFAF
|
Lithium carbonate | Lithium carbonate | Central Nervous System | 9,159 |
|
Lithium carbonate 200mg modified-release tablets
0402030K0AAAIAI
|
Lithium carbonate | Lithium carbonate | Central Nervous System | 7,620 |
|
Camcolit 400 modified-release tablets
0402030K0BBABAF
|
Camcolit | Lithium carbonate | Central Nervous System | 6,092 |
|
Lithium carbonate 250mg tablets
0402030K0AAACAC
|
Lithium carbonate | Lithium carbonate | Central Nervous System | 3,607 |
|
Liskonum 450mg modified-release tablets
0402030K0BDAAAG
|
Liskonum | Lithium carbonate | Central Nervous System | 1,243 |
|
Lithium carbonate 450mg modified-release tablets
0402030K0AAAGAG
|
Lithium carbonate | Lithium carbonate | Central Nervous System | 362 |
|
Camcolit 250 tablets
0402030K0BBAAAC
|
Camcolit | Lithium carbonate | Central Nervous System | 5 |
|
Lithium carbonate 200mg/5ml oral suspension
0402030K0AAAPAP
|
Lithium carbonate | Lithium carbonate | Central Nervous System | No data available |
|
Lithonate 400mg modified-release tablets
0402030K0BGAAAF
|
Lithonate | Lithium carbonate | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.